Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, E. A.
Right arrow Articles by Spitz, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, E. A.
Right arrow Articles by Spitz, F. R.
Clinical Cancer Research Vol. 10, 1535-1544, February 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Combined 5-Fluorouracil/Systemic Interferon-ß Gene Therapy Results in Long-Term Survival in Mice with Established Colorectal Liver Metastases

Eugene A. Choi1, Hanqin Lei1, David J. Maron1, Rosemarie Mick3, James Barsoum4, Qian-chun Yu2, Douglas L. Fraker1, James M. Wilson2 and Francis R. Spitz1,2

1 Department of Surgery, Division of Surgical Oncology, 2 Institute of Human Gene Therapy, 3 Department of Biostatistics and Epidemiology, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; and 4 Biogen, Inc., Cambridge, Massachusetts

Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells. Despite these activities, randomized human trials have failed to identify a clinical benefit for this combination treatment. These limited clinical results may be secondary to the short half-life of recombinant IFN protein and the increased systemic toxicities of 5-FU/IFN combinations. We have previously reported an adenoviral-mediated IFN-ß gene therapy strategy, which may circumvent the pitfalls of recombinant IFN therapy. However, a dose-dependent toxicity and acute inflammatory response to systemically administered adenovirus vectors may limit the clinical application of this therapy. The combination of adenoviral-mediated IFN-ß gene therapy and 5-FU resulted in tumor regression, apoptosis, and improved survival in an established liver metastases model. These therapeutic effects were observed at a significantly lower vector dose than we had previously reported and with limited toxicity. This approach may allow for an effective clinical application of this therapy and warrants additional investigation.




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
D.-M. Koh, G. Brown, Z. Meer, A. R. Norman, and J. E. Husband
Diagnostic Accuracy of Rim and Segmental MRI Enhancement of Colorectal Hepatic Metastasis After Administration of Mangafodipir Trisodium
Am. J. Roentgenol., February 1, 2007; 188(2): W154 - W161.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. M. van Koetsveld, G. Vitale, W. W. de Herder, R. A. Feelders, K. van der Wansem, M. Waaijers, C. H. J. van Eijck, E.-J. M. Speel, E. Croze, A.-J. van der Lely, et al.
Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4537 - 4543.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Streck, P. V. Dickson, C. Y.C. Ng, J. Zhou, J. T. Gray, A. C. Nathwani, and A. M. Davidoff
Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-{beta} Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models
Clin. Cancer Res., August 15, 2005; 11(16): 6020 - 6029.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.